Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
Open Access
- 12 February 2015
- Vol. 70 (4), 311-319
- https://doi.org/10.1136/thoraxjnl-2014-206345
Abstract
Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. Methods This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to 1, forced vital capacity (FVC) and safety. Results Of the 934 patients randomised (QVA149=476 and TIO+FOR=458), 87.9% completed the study. At week 26, non-inferiority was met for SGRQ-C (QVA149 vs TIO+FOR; difference: –0.69 units; 95% CI −2.31 to 0.92; p=0.399). A significantly higher percentage of patients achieved a clinically relevant ≥1 point improvement in TDI total score with QVA149 (49.6%) versus TIO+FOR (42.4%; p=0.033). QVA149 significantly increased pre-dose FEV1 (+68 mL, 95% CI 37 mL to 100 mL; pConclusions QVA149 is non-inferior to TIO+FOR in improving HRQoL, with clinically meaningful and significant improvements in breathlessness and lung function in patients with COPD. Trial registration number NCT01120717.Keywords
This publication has 34 references indexed in Scilit:
- Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEuropean Respiratory Journal, 2013
- Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2009
- Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month studyRespiratory Medicine, 2008
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEuropean Respiratory Journal, 2005
- St. George's Respiratory Questionnaire: MCIDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005
- Impact of preventing exacerbations on deterioration of health status in COPDEuropean Respiratory Journal, 2004
- Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.European Respiratory Journal, 2002
- Effect of temperature on lung function and symptoms in chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 1999
- A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory QuestionnaireAmerican Review of Respiratory Disease, 1992